Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia 22Lymphoma 14Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 12Leukemia, Lymphocytic, Chronic, B-Cell 12Breast Neoplasms 11Prostatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Multiple Myeloma 9Melanoma 9Lymphoma, Follicular 9Neuroblastoma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Ovarian Neoplasms 7Congenital Abnormalities 7Lymphoma, Non-Hodgkin 6Hodgkin Disease 5Neoplasms, Plasma Cell 4Neoplasm Metastasis 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Chronic-Phase 4Glioblastoma 4Fallopian Tube Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Waldenstrom Macroglobulinemia 3Osteosarcoma 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

Ipilimumab 6pembrolizumab 5Nivolumab 5Dacarbazine 5CTLA-4 Antigen 4Carboplatin 3Bevacizumab 3relatlimab 2aflibercept 2Temozolomide 2Ranibizumab 2Radiosurgery 2Paclitaxel 2Lenalidomide 2Immunoglobulin G 2Embolization, Therapeutic 2Disulfides 2Cyclophosphamide 2Colony-Stimulating Factors 2Albumin-Bound Paclitaxel 2AZD 6244 2130-nm albumin-bound paclitaxel 2utomilumab 1ulixertinib 1trametinib 1tebentafusp 1sotrastaurin 1sargramostim 1poly ICLC 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uveal Melanoma × sargramostim × Clear all
NCT01989572 2020-07-07

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Completed
815 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡